Mucosal Delivery of Stabilized Formulations of Exendin
2 Assignments
0 Petitions
Accused Products
Abstract
What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-β-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5° C.
43 Citations
86 Claims
-
1-70. -70. (canceled)
-
71. An aqueous pharmaceutical formulation for intranasal delivery comprising a therapeutically effective amount of exendin-4 or an exendin-4 agonist analog, a permeation-enhancing solubilizing agent, a permeation-enhancing cation chelator, a permeation-enhancing surfactant and optionally a permeation-enhancing viscosity enhancing agent, wherein
a. the solubilizing agent is selected from at least one of the group consisting of hydroxypropyl-β - -cyclodextrin, sulfobutylether-β
-cyclodextrin, dimethyl-β
-cyclodextrin, methyl-β
-cyclodextrin and Cremophor EL,b. the viscosity enhancer is selected from at least one of the group consisting of gelatin, methylcellulose and hydroxypropylmethylcellulose, and c. the surfactant is selected from the group consisting of a least one of phosphotidyl choline, dimyristoly glycero phosphatidylcholine, dilauroyl glycero phosphatidylcholine and L-α
-phosphatidylcholine didecanoyl, and whereind. the formulation provides at least 5% permeation of exendin-4 in an in vitro tissue permeation assay, has a viscosity up to 150 cps, has a pH from 2 to 8 and is stable at least two weeks at 5°
C. - View Dependent Claims (72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)
- -cyclodextrin, sulfobutylether-β
Specification